We are live on ! Find out more
CLLS

Cellectis
CLLS

41 hedge funds and large institutions have $136M invested in Cellectis in 2017 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

3% more funds holding

Funds holding: 40 → 41 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1% less capital invested

Capital invested by funds: $137M → $136M (-$1.12M)

1.28% less ownership

Funds ownership: 16.14% → 14.86% (-1.3%)

26% less call options, than puts

Call options by funds: $494K | Put options by funds: $667K

Holders
41
Holders Change
+1
Holders Change %
+2.5%
% of All Funds
1.02%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
13
Reduced
10
Closed
6
Calls
$494K
Puts
$667K
Net Calls
-$173K
Net Calls Change
+$1.04M

Top Buyers

Rank Fund Capital Flow
1
CS
Credit Suisse
Switzerland
+$1.43M
2
SFM
Sphera Funds Management
Israel
+$1.05M
3
Morgan Stanley
Morgan Stanley
New York
+$906K
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$664K
5
QF
QVT Financial
New York
+$605K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$6.76M
2
Franklin Resources
Franklin Resources
California
-$5.85M
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$1.33M
4
AG
Artal Group
Luxembourg
-$1.19M
5
Lazard Asset Management
Lazard Asset Management
New York
-$776K

CLLS Hedge Fund Activity: Q2 2017 in Review

41 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q2 2017, worth a combined $136M — down 0.82% from $137M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new CLLS positions and 6 closed out — a net gain of 2 holders — while 13 added to existing stakes and 10 trimmed.

The largest buyer was Credit Suisse, opening a new position worth an estimated $1.43M. The largest seller was OrbiMed, cutting an estimated $6.76M.

  • 41 institutional investors held Cellectis (CLLS) as of Q2 2017, up from 40 in Q1 2017.
  • Funds reported $136M of Cellectis stock for Q2 2017, down 0.82% quarter-over-quarter.
  • 8 funds opened new Cellectis positions in Q2 2017 and 6 closed out, a net change of +2 holders.
  • The largest Cellectis buyer in Q2 2017 was Credit Suisse, an estimated $1.43M added.
  • The largest Cellectis seller in Q2 2017 was OrbiMed, an estimated $6.76M sold.

Based on aggregated 13F filings for Q2 2017.